

The following **Listing of the Claims** will replace all prior versions and all prior listings of the claims in the present application:

**Listing of the Claims:**

1. (Canceled)

2. (Canceled)

3. (Currently Amended) A method of treating diabetes and/or microvascular diabetic complications comprising administering C-peptide or a pharmaceutical composition comprising C-peptide to a patient ~~in-a~~ once daily ~~dose~~, wherein said once daily ~~dose~~ **administration** does not include a continuous administration or the presence of release rate-controlling agents.

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

9. (Canceled)

10. (Currently Amended) The method according to claim 3, wherein ~~the~~ **said** C-peptide is human C-peptide

11. (Previously Presented) The method according to claim 3, wherein said C-peptide is a fragment EGSLQ (SEQ ID NO: 2).

12. (Amended) The method according to claim 3, wherein ~~the~~ **said** patient is a human.

13. (Amended) The method according to claim 3, wherein ~~the~~ **said** medicament **pharmaceutical composition** contains 100 to 1800 nmol of C-peptide.

14. (Amended) The method according to claim 3, wherein ~~the~~ **said** medicament **C-peptide** is **in** an uncompromised aqueous solution.

15. (Previously Presented) The method according to claim 3, wherein said complications are diabetic nephropathy, retinopathy or neuropathy.